Navigation Links
Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
Date:8/31/2011

MALVERN, Pa. and LYNBROOK, N.Y., Aug. 31, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, and BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company, today announced that they have dismissed all pending litigation between the Companies and announced plans to move XIAFLEX forward in the clinic for cellulite and human and canine lipoma as well as to collaborate on the initiation of further studies for XIAFLEX for additional indications. Through an amendment and restatement of the Companies' 2008 development and license agreement, the Companies have clarified the rights and responsibilities of the Joint Development Committee.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

Auxilium has been granted the right to initiate studies for the treatment of edematous fibrosclerotic panniculopathy, more commonly known as cellulite, and expects to begin phase Ib clinical studies in early 2012. BioSpecifics will initiate studies for the treatment of human and canine lipomas and plans to initiate clinical studies for both human and canine lipomas shortly. Auxilium will continue to have the option to exclusively license these indications upon completion of BioSpecifics' development work.  Auxilium and BioSpecifics also plan to collaborate on identifying further indications for treatment with XIAFLEX.

Based on the terms of the amended agreement, Auxilium will pay BioSpecifics an opt-in fee at the time of completion by Auxilium of Stage I development of cellulite and will be responsible for all development costs associated with cellulite. Auxilium's opt-in rights remain unchanged with respect to the two lipoma indications. In addition to the opt-in fees, BioSpecifics will continue to be entitled to r
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
2. Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
4. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
5. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
6. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
8. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
9. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BARBARA, Calif. , Dec. 23, 2014 In ... Junior Doctors, Association of Sierra Leone , ... Sierra Leone for the treatment of local health ... While a new dedicated Ebola care center was constructed ... virus, the facility is not available for local Sierra Leonean ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... -- Global Information, Inc. (GII) is pleased to announce ... Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017" by ... The Insulin Delivery Devices Market is Set to Grow ... 2017 GlobalData estimated the global insulin ...
... N.C., Jan. 13, 2012  Facing patent cliffs and shrinking ... either through in-licensing deals or M&A activities - as ... sound strategy, but a difficult one to effectively put ... a business is fraught with potential pitfalls. With 2012 ...
Cached Medicine Technology:Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2
(Date:12/24/2014)... December 24, 2014 Dr. Vu Ho, ... expansion of his practice and med-spa with the addition ... growing list of cosmetic treatments and services. , “Silk ... the skin,” says Dr. Ho. “As a result it ... as wrinkles, sun spots, discolorations or blemishes.” , Similar ...
(Date:12/24/2014)... 24, 2014 Mike Billings , ... with Derek Fenwick, PT, MBA, GCS, Director of ... stem from the passing of the Improving Medicare ... In this taping of the Infinicast, the two leaders ... the Social Security Act to standardize post-acute assessment data ...
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
(Date:12/24/2014)... 2014 The 2014 Market Research ... and in-depth research report on COC industry. For ... information, including its definition, classification, application, industry chain ... This report also presents product specification, manufacturing process, ... by regions, technology and applications. Analysis also covers ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... by Regulatory Approval of Once-Daily Tramadol in, ... for Depression -,LAVAL, QC, Feb. 26 /PRNewswire-FirstCall/ - Labopharm Inc. ... results for the fourth quarter and year ended December 31, ... , "With our first product about to be rolled out ...
... global rare disease community to raise awareness for underserved ... Feb. 26 Shire Human Genetic Therapies (HGT), a ... company, today announced it will join together with the ... Rare Disease Day on February 28, 2009. The purpose ...
... ST. LOUIS, Feb. 26 Stereotaxis, Inc.,(Nasdaq: ... fourth quarter,ended December 31, 2008. Revenue for the ... 18% over the fourth quarter of 2007. Stereotaxis,recognized ... systems in the quarter. Revenue from sales of ...
... 26 MIND Research Institute today,announced that Jim Mazzo, ... was recently elected to MIND,s board of directors. Mr.,Mazzo ... numerous boards and,committees at the University of California ... of Trustees, the Engineering Advisory Board Committee, and,the Eye ...
... Prestigious AwardsLONDON, Feb. 26 The Healthcare ... Frost & Sullivan,s ,Excellence in Healthcare Awards ... London Zoo, London. The industry,s most influential ... their achievements during an evening dinner gala.(Logo: ...
... Footwear by BeechHUNTINGTON BEACH, Calif., Feb. 26 ... Originals line with new adjustable toe separators ... foot therapy can now be customized to fit ... increasing flexibility and helping improve balance and body ...
Cached Medicine News:Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008 14Health News:Shire Celebrates World Rare Disease Day on February 28 2Health News:Shire Celebrates World Rare Disease Day on February 28 3Health News:Shire Celebrates World Rare Disease Day on February 28 4Health News:Stereotaxis Reports Fourth Quarter 2008 Financial Results 2Health News:Stereotaxis Reports Fourth Quarter 2008 Financial Results 3Health News:Stereotaxis Reports Fourth Quarter 2008 Financial Results 4Health News:Stereotaxis Reports Fourth Quarter 2008 Financial Results 5Health News:Stereotaxis Reports Fourth Quarter 2008 Financial Results 6Health News:Stereotaxis Reports Fourth Quarter 2008 Financial Results 7Health News:Jim Mazzo Joins MIND Research Institute's Board of Directors 2Health News:Frost & Sullivan Awards to Celebrate Healthcare Excellence 2Health News:Sandal Evolution(R) Takes a Healthy Step 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: